Phase 2 study of Tolperisone in patients with acute, painful muscle spasms as well as for spasticity
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Tolperisone (Primary)
- Indications Muscle spasticity; Spasm
- Focus Therapeutic Use
- Sponsors Neurana Pharmaceuticals
- 25 May 2017 According to a Neurana media release, , subject to successful Phase 2 and Phase 3 clinical trials, a New Drug Application (NDA) can be filed within four years.
- 11 Mar 2016 New trial record
- 09 Mar 2016 According to Katama media release, there is an open investigational new drug application (IND) for Tolperisone and based upon the results of phase 2 and phase 3 trials a New Drug Application (NDA) may be filed within three years.